U.S. Pharma Stock News

NYSE:HIG
NYSE:HIGInsurance

Is Hartford (HIG) Offering An Opportunity After Recent Share Price Pullback And Strong Multi Year Gains

If you are wondering whether Hartford Insurance Group's current share price still reflects good value, this article walks through what the numbers actually say rather than relying on headlines or hype. The stock last closed at US$132.93, with a 4.5% decline over the past week and a 6.4% decline over the past month, while the 1 year return stands at 13.7% and the 3 and 5 year returns are 114.1% and 117.3% respectively. Recent coverage around Hartford Insurance Group has focused on the company...
NYSE:VIA
NYSE:VIASoftware

Via Transit Wins Highlight Undervalued Growth Story In Public Transport Digitisation

Via Transportation (NYSE:VIA) reports material improvements in city transit performance in the City of Mobile, including better reliability and staffing outcomes without additional budget. The company expands its work with Transport for West Midlands in the UK, adding Citymapper integration to support future regional transit planning. These developments highlight Via’s growing role as a partner for large scale public transit transformation across multiple geographies. Via Transportation,...
NYSE:MCY
NYSE:MCYInsurance

California Driving Law Shifts Reframe Mercury General Risk And Return Profile

California has introduced new driving laws affecting ignition interlock devices, penalties for intoxication related vehicular manslaughter, and rules for autonomous vehicles and electric motorcycles. Mercury General (NYSE:MCY), through its Mercury Insurance brand, has highlighted these legal updates for policyholders and investors. The company views the changes as relevant for risk assessment, claims patterns, and driver behavior in its core California market. For Mercury General, which...
NasdaqGM:MVIS
NasdaqGM:MVISElectronic

MicroVision (MVIS) Is Down 7.0% After Revenue Drop And Narrower Losses In 2025 Results

MicroVision, Inc. has reported its full-year 2025 results, with sales of US$1.21 million compared to US$4.70 million in 2024 and a net loss of US$94.98 million versus US$96.92 million, while basic loss per share from continuing operations narrowed to US$0.35 from US$0.46. The combination of falling revenue and a slightly smaller loss highlights the company’s challenge of scaling its business while still tightly managing costs. With sales declining year over year but net loss narrowing, we’ll...
NYSE:ORA
NYSE:ORARenewable Energy

Is It Too Late To Consider Ormat Technologies (ORA) After 54% One Year Share Price Jump

If you are wondering whether Ormat Technologies' current share price lines up with its underlying value, this article will walk you through the numbers in a straightforward way. The stock closed at US$110.38, with returns of 1.4% over 7 days, a 10.4% decline over 30 days, a 2.9% decline year to date, and a 54.4% return over 1 year, alongside 3 year and 5 year returns of 39.8% and 49.7% respectively. Recent coverage has focused on Ormat Technologies as a long standing player in the US...
NYSE:DAL
NYSE:DALAirlines

Is Delta Air Lines (DAL) Pricing Reflect Recent Pullback And Reassessment Of US Airlines

If you are wondering whether Delta Air Lines is priced attractively right now, this article walks through what the current share price might imply about its underlying value. The stock last closed at US$58.78, with a 7 day return of 0.4% decline, a 30 day return of 17.7% decline, a year to date return of 14.9% decline, a 1 year return of 27.3%, and a 3 year return of 83.8%. Recent coverage around Delta has focused on how investors are reassessing major US airlines as a group, including...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments?

Ardelyx recently reported the peer-reviewed publication of pooled clinical data showing its IBSRELA (tenapanor) therapy delivered earlier and sustained symptom relief in adults with IBS-C, with no new safety concerns identified. The analysis offers clinicians practical guidance on treatment duration and symptom timelines, potentially influencing how IBSRELA is positioned and used in everyday care. We’ll now examine how this new evidence of earlier and sustained IBS-C symptom relief could...
NYSE:SR
NYSE:SRGas Utilities

Spire’s US$11.2 Billion Decade-Long Investment Plan Might Change The Case For Investing In Spire (SR)

Zacks Equity Research recently highlighted Spire Inc.’s long-term infrastructure and innovation plans, including an expected US$11.20 billion in capital investments over the next decade, alongside its current 3.59% dividend yield and analyst estimates for long-term earnings growth. The analysis underscores how these planned investments and anticipated earnings expansion could influence Spire’s role in a gas utility sector balancing aging infrastructure, renewable competition, and the...
NYSE:MUX
NYSE:MUXMetals and Mining

McEwen Mining (MUX) Q4 Profit Jump Challenges Bearish Valuation Narratives

McEwen (MUX) closed out FY 2025 with Q4 revenue of US$64.6 million and basic EPS of US$0.70, alongside net income of US$38.1 million, putting a clear marker on its latest financial run rate. Over the year, quarterly revenue ranged from US$35.7 million in Q1 to US$64.6 million in Q4, while basic EPS moved between a loss of US$0.12 and a gain of US$0.70, giving investors a wide view of how profitability has tracked against the top line. Overall, the results point to firmer margins in the latest...
NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate Claude Tie Up Tests AI Disintermediation And Workflow Stickiness

Clarivate (NYSE:CLVT) has integrated its regulatory intelligence with Anthropic's Claude AI assistant. The collaboration embeds Clarivate's regulatory data directly into biopharma, biotech, and medtech AI workflows. The move is aimed at supporting regulatory affairs teams by keeping trusted data closer to day to day decision making. Clarivate focuses on data, analytics, and workflow tools for research driven industries, and life sciences is a core part of that mix. By plugging its...
NYSE:CNH
NYSE:CNHMachinery

CNH Industrial Eyes Stickier Revenue With New Antenna And Dealer Expansion

Hemisphere GNSS, a brand of CNH Industrial, has introduced the A65 GNSS antenna in partnership with Calian Group, targeting better interference rejection and easier upgrades for precision agriculture systems. Forrester Farm Equipment is acquiring AG-Industrial, expanding the CNH dealer network and deepening cooperation on parts and service support across North America. CNH Industrial (NYSE:CNH), trading at about $10.65, has a mixed recent performance, with a 13.9% return year to date but...
NYSE:TOL
NYSE:TOLConsumer Durables

Is It Time To Reassess Toll Brothers (TOL) After Recent Share Price Pullback?

If you are wondering whether Toll Brothers is still reasonably priced after a strong run, you are not alone. The stock’s current valuation is a key question for many investors right now. The share price closed at US$136.69, with a 7.4% decline over the last 7 days and a 15.3% decline over the last 30 days, while the 1 year return sits at 31.4% and the 3 year and 5 year returns are 143.5% and 165.4% respectively. Recent news flow around Toll Brothers has focused on broader housing market...
NasdaqGS:XP
NasdaqGS:XPCapital Markets

How Investors May Respond To XP (XP) Adding Kalshi Prediction Markets As A New Asset Class

Kalshi recently announced a partnership with Brazilian broker XP Inc. to offer regulated prediction markets to XP clients holding international investment accounts, initially via the Clear Corretora platform and focused on financial and economic event-based contracts. This move introduces a new asset class alongside equities, ETFs, bonds, and derivatives on XP’s international platform, underscoring XP’s push to broaden product diversification and financial innovation for Brazilian investors...
NYSE:INGM
NYSE:INGMElectronic

The Bull Case For Ingram Micro Holding (INGM) Could Change Following Equity Sale And New Buyback Plan

In the past week, Ingram Micro Holding Corporation completed a US$200.00 million follow-on equity offering of 8,988,764 common shares at US$22.25 each, while also announcing a new US$100.00 million share repurchase program tied to secondary offerings by existing shareholders. This combination of fresh equity issuance, a major sell-down by Platinum Equity LLC, and a buyback authorization highlights a significant reshaping of Ingram Micro’s shareholder base without directly changing its...
NYSE:ATO
NYSE:ATOGas Utilities

A Look At Atmos Energy (ATO) Valuation As Infrastructure Spending Accelerates Under Lower Interest Rates

Infrastructure build out becomes the key story for Atmos Energy Atmos Energy (ATO) is ramping up its infrastructure program, with US$3.6b allocated in fiscal 2025 and a planned US$4.2b in 2026, supported by lower interest rates that ease financing costs. See our latest analysis for Atmos Energy. The stock’s recent move appears to reflect investors reacting to this heavier infrastructure spend, with a 7.17% 1 month share price return and a 28.61% 1 year total shareholder return suggesting...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus

Why Axsome’s Latest Legal and Regulatory Headlines Matter for Shareholders Axsome Therapeutics (AXSM) is back in focus as investors weigh a new shareholder investigation into past AXS-07 regulatory disclosures, alongside an upcoming FDA decision on AXS-05 for Alzheimer’s disease agitation. See our latest analysis for Axsome Therapeutics. At a share price of $156.08, Axsome’s 1 day share price return of 1.27% and 90 day share price return of 5.34% contrast with a 30 day share price return of a...
OTCPK:LKNC.Y
OTCPK:LKNC.YHospitality

First Beijing Investment Stake Reshapes Governance Debate At Luckin Coffee

First Beijing Investment Ltd has become a major shareholder in Luckin Coffee (OTCPK:LKNC.Y) after acquiring over 107,000,000 shares. The purchase gives First Beijing Investment Ltd control of more than 5% of the company, crossing the threshold for a significant ownership stake. This change in the shareholder base introduces a new institutional holder that could influence future discussions around governance and strategy. Luckin Coffee operates a large coffee chain footprint in China,...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

DENTSPLY SIRONA Bets On Dental MRI To Reframe Growth Story

DENTSPLY SIRONA (NasdaqGS:XRAY) and Siemens Healthineers secured FDA clearance for the MAGNETOM Free.Max Dental Edition, described as the first MRI system dedicated to dental use. The company is preparing for a US launch, supported by clinical trial data and upcoming training programs for dental professionals. The system is designed to offer high contrast, non ionizing imaging for applications such as endodontics and TMJ assessment. At a current share price of $11.54, DENTSPLY SIRONA comes...
NYSE:HNGE
NYSE:HNGEHealthcare

Is It Time To Reassess Hinge Health (HNGE) After Its Recent Share Price Rebound?

If you are wondering whether Hinge Health is attractively priced or already baking in a lot of optimism, this article is designed to help you frame that question clearly. The stock last closed at US$45.00, with a 16.1% gain over the past 30 days, but a 2.5% decline over the last week and a 1.2% decline year to date. This hints at shifting views on both its potential and its risks. Recent news coverage has focused on Hinge Health's position as a listed musculoskeletal care company, along with...
NasdaqGM:TNDM
NasdaqGM:TNDMMedical Equipment

The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Android Launch Of Tandem Mobi App

In March 2026, Tandem Diabetes Care announced that its FDA-cleared Tandem Mobi mobile app is now available to U.S. Android users via Google Play, enabling direct control of the Tandem Mobi automated insulin delivery system from select Google Pixel 6–10 and Samsung Galaxy S21–S25 smartphones. This expansion to Android significantly broadens the pool of potential users who can integrate Tandem Mobi into their existing devices, strengthening the appeal of Tandem’s connected diabetes management...
NYSE:CPA
NYSE:CPAAirlines

Is Copa Holdings (CPA) Pricing Reflect Long Term Latin American Air Travel Expectations

If you are wondering whether Copa Holdings at around US$110 per share is offering good value right now, looking closely at how it is priced versus its fundamentals can help you frame that decision. The stock has had a mixed run, with a 25.5% return over the last year and a 52.9% return over three years, alongside shorter term moves such as a 26.7% decline over the last 30 days and an 11.7% decline over the past week. Recent news around Copa Holdings has focused on its position in Latin...
NYSE:RDW
NYSE:RDWAerospace & Defense

NASA Grant Puts Redwire’s PIL-BOX Drug Research In Investor Focus

NASA awarded Redwire (NYSE: RDW) an additional US$4 million for drug development research on the International Space Station. The funding supports Redwire's Pharmaceutical In-space Laboratory, known as PIL-BOX, expanding its existing contract with NASA. The project focuses on using microgravity to study and manufacture potential future pharmaceutical treatments. For investors watching the space infrastructure theme, Redwire sits at the intersection of space hardware and applied research,...
NasdaqGS:ROCK
NasdaqGS:ROCKBuilding

Is Gibraltar Industries (ROCK) Now A Potential Opportunity After A 36.9% One Year Share Price Drop

Wondering whether Gibraltar Industries is starting to look like value at today’s price, or if the stock’s risks still outweigh the potential upside? This article is built to help you weigh that up using clear valuation checks. After closing at US$41.27, the stock has seen a 2.6% gain over the last 7 days. That sits against a 23.7% decline over 30 days and a 36.9% decline over the past year, with returns of 17.7% decline year to date, 11.2% decline over 3 years and 52.7% decline over 5...
NasdaqGS:TTAN
NasdaqGS:TTANSoftware

ServiceTitan (TTAN) Revenue Growth Of 26.5% Tests Bearish Profitability Narratives

ServiceTitan (TTAN) just posted another quarter of rapid top line expansion, with Q3 FY 2026 revenue at US$249.2 million and a basic EPS loss of US$0.42, against a backdrop of 26.5% revenue growth over the past year and a trailing twelve month net loss of US$298.1 million. The company has seen quarterly revenue move from US$192.9 million in Q2 FY 2025 to US$249.2 million in Q3 FY 2026. Over the same period, basic EPS losses ranged from US$1.43 in Q2 FY 2025 to US$0.42 in the latest quarter,...